XML 202 R84.htm IDEA: XBRL DOCUMENT v3.24.3
COMMITMENTS AND CONTINGENCIES (Details Narrativec) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Nov. 21, 2023
Jun. 26, 2022
Jul. 31, 2021
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Dec. 31, 2022
Stock based compensation       $ 109,636 $ 109,636 $ 326,525 $ 214,505 $ 323,957  
Payment of additional tax           99,644   99,644  
Description for advisory agreement     the Company paid $100,000. The $100,000 bonus was incurred and settled within 2022. Finally, the Consultant received a total of 10,000 shares of the Company’s common stock, 2,000 of such shares that have been previously issued pursuant to previous agreements and additional 15,258 shares that were issued on February 2, 2023, based on the amendment signed on February 1, 2023            
Additional stock consideration           $ 264,000      
Complementary compensation Shares           440,000      
Stocked based compensation           $ 1,103,200 214,505 577,931 $ 24,401
Compensation for non-pecuniary damage amounting               21,744  
General and administrative expenses               164,859  
Four Third Party Consultants [Member]                  
Awarded shares 970,000                
Awarded share value $ 999,100                
Phase 1 [Member]                  
Project cost   $ 838,450              
Phase 2 [Member]                  
Project cost   $ 907,084              
National Medicines Agency [Member] | General and administrative expenses [Member]                  
Stock based compensation       $ 264,750 $ 0 728,250 $ 0 77,250  
Imposed fine           $ 16,214   16,214  
Stocked based compensation               $ 77,250